This Phase I, two-cohort, dose-escalation trial of talazoparib monotherapy in molecularly unselected patients with advanced hematologic malignancies (ClinicalTrials.gov Identifier: NCT01399840) was conducted prior to the approval of talazoparib to treat BRCA1/2-mutated HER2- advanced breast cancer [25,26] and in parallel with the solid tumor Phase I study (NCT01286987) that determined the talazoparib MTD at 1 mg once daily [22]. The gene discussed is BRCA1; the disease is breast cancer.